BIOTRONIK and Egg Medical Form Strategic Alliance to Improve Radiation Protection for Interventional Healthcare Workers

LAKE OSWEGO, Ore., United States, January 13, 2025 – BIOTRONIK, a global leader in in cardiovascular, endovascular, and neuromodulation solutions is pleased to announce the first patient enrollment in the second arm of the BIO-CONDUCT study, an FDA-approved investigational device exemption (IDE) trial examining the use of the investigational BIOTRONIK next-generation Solia CSP S pacing lead when implanted in the left bundle branch area (LBBA). Left bundle branch area pacing is an emerging technique providing a more physiologic activation of cardiac tissue in patients needing ventricular pacing

BIOTRONIK, a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) labeling approval of its Selectra 3D catheter in conjunction with its Solia S lead for use in left bundle branch area pacing (LBBAP). The two products represent the first and only FDA-approved stylet-driven lead and dedicated delivery catheter system approved for LBBAP. The Solia S lead and Selectra 3D catheter have been used in more than 80,000 patients worldwide. 1 The additional indication supports their use in the evolving technique of pacing the heart’s natural

BIOTRONIK, a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward. The move is being made in response to overwhelming recent clinical data demonstrating superior diagnostics and decreased complication risk of DX compared to traditional high-voltage systems. 1-4 “Based on the current evidence, it is clear we must focus on what is proving to be a lower risk technology with added benefits,” said Dr. Alexander Uhl, BIOTRONIK CEO. “Therefore, we have made the decision to offer only DX

BIOTRONIK announced the milestone achievement of 100,000 implanted single lead implantable cardioverter-defibrillators (ICDs) equipped with DX Technology enabling direct atrial sensing for atrial fibrillation (AF) detection and monitoring. Since the introduction of this unique technology in 2009, DX ICDs are used today by clinicians in more than 80 countries around the world. “Reaching this significant milestone, BIOTRONIK stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful

For the first time, a panel of spinal cord stimulation (SCS) experts has developed best practices in the nascent field of remote SCS device management. The recommendations were recently published in Neuromodulation. 1 When cardiac remote monitoring emerged in the early 2000s, an expert consensus responded by establishing a framework of principles to optimize the management of cardiovascular implantable electronic devices (CIEDs) in 2008. Similar wireless technology is available for the treatment of chronic pain patients, and the publication provides critical guidance on best practices to

BIOTRONIK is proud to introduce the Micro Rx™ catheter, a novel rapid exchange microcatheter developed to easily enhance guidewire support during percutaneous coronary interventions (PCI). This cutting-edge device, exclusively distributed by BIOTRONIK, is manufactured by IMDS (Interventional Medical Device Solutions). Micro Rx catheter marks the fourth IMDS product BIOTRONIK has brought to the U.S., creating a compelling portfolio of devices which includes NHancer Rx, TrapIT, and ReCross catheters. The Micro Rx catheter features a reinforced distal shaft with a core wire between two layers of